Eliminating the Medicare Coverage Gap for Intranasal Naloxone and Nicotine Replacement Therapy
This Viewpoint explores how FDA approval of intranasal naloxone and nicotine replacement therapy as over-the-counter drugs adversely affects Medicare patients because the treatments are no longer covered and urges policymakers to address this coverage gap.
Authors
- Brian S. Barnett (ORCID: https://orcid.org/0000-0002-8963-5701)
- Robert A. Kleinman (ORCID: https://orcid.org/0000-0001-5455-0073)
Institutions
- Cleveland Clinic (US)
- Centre for Addiction and Mental Health (CA)
- University of Toronto (CA)
- Cleveland Clinic Lerner College of Medicine (US)
- Case Western Reserve University (US)
Publication Details
- Journal
- JAMA
- Published
- 2025-02-05
- DOI
- https://doi.org/10.1001/jama.2024.28394
- Primary Topic
- Smoking Behavior and Cessation
- Type
- article
- Field-Weighted Citation Impact
- 0.00